CN101244105B - Pseudo-ginseng standard extract P1237, its pharmaceutical combination, its preparing method and its uses - Google Patents
Pseudo-ginseng standard extract P1237, its pharmaceutical combination, its preparing method and its uses Download PDFInfo
- Publication number
- CN101244105B CN101244105B CN2008100581451A CN200810058145A CN101244105B CN 101244105 B CN101244105 B CN 101244105B CN 2008100581451 A CN2008100581451 A CN 2008100581451A CN 200810058145 A CN200810058145 A CN 200810058145A CN 101244105 B CN101244105 B CN 101244105B
- Authority
- CN
- China
- Prior art keywords
- ethanol
- extract
- standard extract
- radix notoginseng
- panax notoginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a notoginseng standard extract P1237 for the treatment of cancer, a drug combination comprising the active components of the extract, the oral liquid and injection, the preparation method, the pharmaceutical application of the notoginseng standard extract P1237 and the drug combination as cancer treatment drugs. The invention is characterized in that the oral liquid preparation of the notoginseng standard extract P1237 is mainly composed of ginsenoside Rh4, ginsenoside Rh1 and notoginsenoside T5. The notoginseng standard extract has the advantages that according to the research of anti-tumor activity and induction of apoptosis, the notoginseng standard extract P1237 can inhibit the proliferation of in vitro human tumor cell lines K562, HL-60, BGC-823, COC1, and MCF-7; the in vitro anti-tumor activity is outstanding; what's more, the toxicity of the notoginseng standard extract P1237 is not shown obviously, so the safety is high.
Description
Technical field: the present invention relates to drug world, particularly, relate to a kind of Panax notoginseng standard extract P that is used for the treatment of cancer
1237, be the pharmaceutical composition that active component is formed with this extract, its preparation method, and Panax notoginseng standard extract P
1237And pharmaceutical composition is as the medical usage of treatment cancer drug.
Background technology: Radix Notoginseng is the famous Chinese crude drug of China, and application clinically is very extensive, but the Panax notoginseng standard extract P that goes out with Radix Notoginseng rhizome extraction separation
1237Be developed to the medicine that is used for the treatment of cancer, do not appear in the newspapers in the prior art.
Summary of the invention: the object of the present invention is to provide a kind of Panax notoginseng standard extract P that is used for the treatment of cancer
1237, be the pharmaceutical composition that active component is formed with this extract, and oral liquid and injection, its preparation method, and Panax notoginseng standard extract P
1237And pharmaceutical composition is as the medical usage of treatment cancer drug.
In order to realize above-mentioned purpose of the present invention, the invention provides following technical scheme:
Panax notoginseng standard extract P
1237, can obtain by following method:
Get the Radix Notoginseng rhizome, add the ethanol (V/W) of 10 times of amounts 70%, reflux, extract, 3 times, each 2 hours, merge ethanol extract, reclaim solvent, the dry ethanol extraction that gets, after the low amounts of water dissolving, by the D101 macroporous adsorbent resin column chromatography, first water eluting, reuse 80% ethanol elution merges ethanol elution, reclaims solvent, drying obtains Radix Notoginseng total arasaponins, and reuse 95% ethanol heating for dissolving is adsorbed on 200 ~ 300 purpose silica gel, room temperature volatilizes, and pulverizes, and it is standby to cross 60 mesh sieves; Get 200 ~ 300 order silica gel dress post, carry out column chromatography for separation; With 9: 1: the chloroform-methanol of 0.1V/V-water mixed solvent eluting, 4L were one and flow part, collect respectively stream part respectively, and the 4th ~ 5 flows a part merging, reclaims solvent, and drying obtains standard extract P
1237
Panax notoginseng standard extract P of the present invention
1237, ginsenoside Rh wherein
4, the ginsenoside Rh
1Be not less than 50% with the content of arasaponin T5.
The present invention provides a kind of Chinese medicine composition for the treatment of cancer simultaneously, by Panax notoginseng standard extract P
1237And/or pharmaceutically acceptable carrier is formed.
A kind of medicine for the treatment of cancer of the present invention is a raw material with the Radix Notoginseng, oral liquid or the injection that can be made by following method:
Get the Radix Notoginseng rhizome, add the ethanol (V/W) of 10 times of amounts 70%, reflux, extract, 3 times, each 2 hours, merge ethanol extract, reclaim solvent, the dry ethanol extraction that gets, after the low amounts of water dissolving, by the D101 macroporous adsorbent resin column chromatography, first water eluting, reuse 80% ethanol elution merges ethanol elution, reclaims solvent, drying obtains Radix Notoginseng total arasaponins, and reuse 95% ethanol heating for dissolving is adsorbed on 200 ~ 300 purpose silica gel, room temperature volatilizes, and pulverizes, and it is standby to cross 60 mesh sieves; Get 200 ~ 300 order silica gel dress post, carry out column chromatography for separation; With 9: 1: the chloroform-methanol of 0.1V/V-water mixed solvent eluting, 4L were one and flow part, collect respectively stream part respectively, and the 4th ~ 5 flows a part merging, reclaims solvent, and drying obtains standard extract P
1237, add then pharmaceutically acceptable carrier routinely formulation method make oral liquid or injection.
In addition, the invention provides Panax notoginseng standard extract P
1237Preparation method, get the Radix Notoginseng rhizome, add 10 times of amount ethanol (V/W) of 70%, reflux, extract, 3 times, each 2 hours, merge ethanol extract, reclaim solvent, the dry ethanol extraction that gets, after the low amounts of water dissolving, by the D101 macroporous adsorbent resin column chromatography, first water eluting, reuse 80% ethanol elution merges ethanol elution, reclaims solvent, drying obtains Radix Notoginseng total arasaponins, and reuse 95% ethanol heating for dissolving is adsorbed on 200 ~ 300 purpose silica gel, room temperature volatilizes, and pulverizes, and it is standby to cross 60 mesh sieves; Get 200 ~ 300 order silica gel dress post, carry out column chromatography for separation; With 9: 1: the chloroform-methanol of 0.1V/V-water mixed solvent eluting, 4L were one and flow part, collect respectively stream part respectively, and the 4th ~ 5 flows a part merging, reclaims solvent, and drying obtains standard extract P
1237
Panax notoginseng standard extract P of the present invention
1237And be the application of Chinese medicine composition in the medicine of preparation treatment Cancerous disease of effective ingredient, and the application in the medicine of preparation treatment Cancerous disease.
The Panax notoginseng standard extract P that the present invention goes out with Radix Notoginseng rhizome extraction separation
1237In with the ginsenoside Rh
4(ginsenoside Rh4), the ginsenoside Rh
1(ginsenoside Rh
1) and arasaponin T5 (notoginsenoside T5). be Main Ingredients and Appearance, three kinds of structure of matter figure are as follows, with Panax notoginseng standard extract P
1237Make the Panax notoginseng standard extract P that is used for the treatment of cancer for effective ingredient
1237Oral agents or injection preparation.
Panax notoginseng standard extract P
1237Concrete separation method step is:
1. get Radix Notoginseng rhizome 4.8kg, add the ethanol (V/W) of 10 times of amounts 70%, reflux, extract, 3 times, each 2 hours, merge ethanol extract, reclaim solvent, the dry ethanol extraction 1.9kg that gets.
2. ethanol extraction is with after the low amounts of water dissolving, by D101 macroporous adsorbent resin (15kg, the column chromatography of Φ 20cm * 80cm), discard with the 20kg water elution earlier, reuse 80% ethanol 25kg eluting merges ethanol elution, reclaim solvent, drying obtains Radix Notoginseng total arasaponins 750g.
3. the gained Radix Notoginseng total arasaponins is adsorbed on the silica gel (200 ~ 300 order) of 1.5kg with 95% ethanol 3L heating for dissolving, and room temperature volatilizes, and pulverizes, and it is standby to cross 60 mesh sieves.
4. get 4.5kg silica gel (200 ~ 300 order) dress post (Φ 12cm * 120cm), carry out column chromatography for separation.
5. (9: 1: 0.1V/V) mixed solvent eluting, 4L were one and flow part, collect respectively stream part respectively, and the 4th ~ 5 flows a part merging, reclaims solvent, and drying obtains standard extract P with chloroform-methanol-water
1237Pale yellow powder 15g.
Technological process of production figure sees accompanying drawing 1.
With the ginsenoside Rh
4(ginsenoside Rh
4), the ginsenoside Rh
1(ginsenosideRh
1), arasaponin T5 (notoginsenoside T5). be the Panax notoginseng standard extract P of main component
1237Be used to prepare the oral agents preparation for the treatment of cancer and injection etc.
Panax notoginseng standard extract P of the present invention
1237During as medicine, can directly use, perhaps use with the form of pharmaceutical composition.This pharmaceutical composition contains 0.1-99%, is preferably the extract of the present invention of 0.5-90%, and all the other are acceptable on the materia medica, to nontoxic and inert pharmaceutically suitable carrier of humans and animals and/or excipient.
Described pharmaceutical carrier or excipient are one or more solids, semisolid and liquid diluent, filler and pharmaceutical preparation adjuvant.Pharmaceutical composition of the present invention is used with the form of per weight dose.The method that the Pharmaceutical composition of extract adopts pharmaceutical field to generally acknowledge is prepared into various dosage forms, as liquid preparation (injection, suspensoid, Emulsion, solution, syrup etc.), solid preparation (tablet, capsule, granule, electuary etc.), spray, aerosol etc.Medicine of the present invention can carry out the treatment of cancer therapy drug through route of administration such as injection (intravenous injection, intravenous drip, intramuscular injection, lumbar injection, subcutaneous injection) and oral, sublingual administration, mucosa dialysis.
Description of drawings:
Fig. 1 is Panax notoginseng standard extract P of the present invention
1237Preparation technology's flow chart;
Fig. 2 is that the present invention is with Panax notoginseng standard extract P
1237Be made as first batch of medicine Pn4 that effective ingredient makes growth inhibited effect sketch map to S180;
Fig. 3 is that the present invention is with Panax notoginseng standard extract P
1237Be made as second batch of medicine Pn4 that effective ingredient makes growth inhibited effect sketch map to H22;
Fig. 4 is that the present invention is with Panax notoginseng standard extract P
1237Be made as the 3rd batch of medicine Pn4 that effective ingredient makes growth inhibited effect sketch map to H22;
Fig. 5 is that the present invention is with Panax notoginseng standard extract P
1237Be made as the 4th batch of medicine Pn4 that effective ingredient makes growth inhibited effect sketch map to H22;
Fig. 6 is that the present invention is with Panax notoginseng standard extract P
1237Be made as the 5th batch of medicine Pn4 that effective ingredient makes growth inhibited effect sketch map to H22;
Fig. 7 is Panax notoginseng standard extract P of the present invention
1237Influence to mouse bearing liver cancer H22 tumor body;
The cellular morphology of Fig. 8 negative control group HL-60;
Fig. 9 100ug/ml Panax notoginseng standard extract P1237 effect HL-60 cell, 24h;
Figure 10 200ug/ml Panax notoginseng standard extract P1237 effect HL-60 cell, 24h;
The HL-60 cell of the detected apoptosis of Figure 11 POD
Figure 12 negative control
Figure 13 100 μ g/ml Panax notoginseng standard extract P
1237Influence and apoptotic detection by quantitative to the HL-60 cell cycle distribution;
Figure 14 200 μ g/ml Panax notoginseng standard extract P
1237Influence and apoptotic detection by quantitative to the HL-60 cell cycle distribution;
Figure 15 positive control vp-16 is to the influence and the apoptotic detection by quantitative of HL-60 cell cycle distribution.
The specific embodiment:
Below further set forth Panax notoginseng standard extract P of the present invention by testing example
1237And the beneficial effect of pharmaceutical composition and medicine, these test examples have comprised the pharmacodynamics test of extract of the present invention and medicine and toxicological test etc.
Panax notoginseng standard extract P
1237Anti-tumor activity and induce HL-60 apoptosis test:
Malignant tumor serious threat human health, the death toll in the annual whole world reaches more than 6,000,000.The sickness rate that enters some tumor of 21 century is still increasing, and the task of control cancer is still very arduous.People are still striving to find better antitumor drug now.In recent years, along with the develop rapidly of subjects such as molecular biology and genetic engineering, people have had more deep understanding from organ, cell, molecule and gene level to malignant tumor, have brought new thinking for the research and development of antitumor drug.Especially area of computer aided drug design, combinatorial chemistry combine with the high-flux medicaments sifting technology, make the extraction, screening, structure of modification of anti-tumor active substance and complete synthesis more rationally quick, and various new medicines, preparation are come out one after another.Particularly newtype anticarcinogen such as new vessels formation inhibitor, monoclonal antibody medicine, differentiating inducer and the short apoptosis medicine of developing at some key link of malignant tumor generation development etc. are all come out one after another, and make the research of antitumor drug enter new epoch.But the antitumor drug of having developed is also existing problems such as poor selectivity, toxic and side effects are big, drug resistance in varying degrees, therefore from occurring in nature seek the selectivity height, toxic and side effects anti-cancer agent little, novel structure remains the problem that merits attention.
Radix Notoginseng is the root of Araliaceae herbaceos perennial Radix Notoginseng (Panax notoginseng), and main product is called Radix Notoginseng, Radix Notoginseng in Yunnan, Guangxi and other places.The traditional Chinese medical science thinks that the Radix Notoginseng nature and flavor are little sweet, and property is flat, goes into liver, kidney, stomach warp, and activating blood circulation to dissipate blood stasis is arranged, and the merit of promoting the circulation of QI to relieve pain is applicable to congestion pain, traumatic injury etc.Recent studies shows, the main active of Radix Notoginseng is arasaponin (Panax notoginoside, PNS), its content in tuber is about 12%, isolate 20 kinds of dammarane type saponin at present from each position of Radix Notoginseng, main component wherein is consistent with Radix Ginseng, i.e. panoxadiol's type saponin Rb1, protopanaxatriol ginsenoside Rg1, but content is than the Radix Ginseng height.Pharmacological research shows that arasaponin has anastalsis, can shorten clotting time and prothrombin time, and can reduce capillary permeability; Obviously coronary blood flow increasing reduces myocardial oxygen consumption, and decreased heart rate, and the effect that can resist pituitrin produce rapid and persistent hypotensive effect; Can excited cardiac muscle and cardiotonic is arranged; Can promote the accumulation of hepatic glycogen and liver protection effect is arranged.Its water extract has in various degree inhibitory action to virus and various skin fungus.The contained slender acanthopanax saponin A of Radix Notoginseng still has tangible diuresis, and in addition, saponin still has haemolysis.Other reports that arasaponin can increase cAMP content in the mouse boosting cell, thereby improves splenocyte lethality, raise immunity.The notoginseng preparation is usually used in treating tumor such as gastric cancer, to hemorrhage after Liver and kidney fibrosis and the chemotherapy certain curative effect is also arranged.Adopt morphocytology, cytochemistry, cell surface membrane Detection of antigen technology etc. studies show that, arasaponin R1 can induce an early young grain leukemia HL-60 cell to transform H to granulocyte
3TdR, H
3UR mixes experiment and shows that arasaponin R1 can suppress the synthetic of cell DNA, RNA, may be one of mechanism of its antitumor action.
Apoptosis (apoptosis) claims apoptosis (programmed cell death) again, it is a kind of special dead form of cell, have important physical and pathological significance, the disorder of its regulatory function plays a significant role in the generation of malignant tumor.Many anticarcinogens all have the effect of inducing apoptosis of tumour cell, and its anticarcinogenic effect is relevant with the ability of its inducing apoptosis of tumour cell.It is relevant with the adjusting of its apoptosis-related genes expression whether apoptosis takes place, and the latter can be divided into the apoptosis promotion and suppress two kinds of genes on function.Apoptosis promotes that gene comprises c-myc, RP-8:TRPM-2, bax, bcl-
Xs, bad, bak, wild type P53 etc., Inhibit Genes comprises bcl-2, bcl-
XL, raf, mutant p53 etc.The release of Bax inducing cell pigment C activates Caspase-3, causes film bubble formation, karyorrhexis and cell death; And Bcl-2 may promote gene Bax antagonism with apoptosis, suppresses cytochrome C and is released into kytoplasm from mitochondrion, stops the activation of cytochrome C to Caspase protease.Bcl-2 can not promote that glutathion enters nucleus, thereby changes redox reaction in the nucleus, stops the activation of caspase protease, suppresses apoptosis.Usually the ratio of Bcl-2 and Bax protein level has determined apoptosis whether to take place.
Panax notoginseng standard extract PP1237 separates a class standard extract that obtains from Radix Notoginseng, be that 3 kinds of dammarane join sugar.The anti-tumor activity of saponin is subjected to the influence of parent nucleus and glycosyl.By to the contrast of the activity of saponin Rh series, the cytotoxicity that can infer saponin Rh is along with the appearance of the disappearance of glycosyl and two keys and strengthen.Radix Notoginseng is the araliaceae ginseng plant, is the peculiar species of China, has long medicinal history and high medical value.Modern pharmacological research shows that Radix Notoginseng polysaccharide has antitumor action.Because Panax notoginseng standard extract P
1237Difficulty of extracting in Radix Ginseng and content are very little, both at home and abroad relevant Panax notoginseng standard extract P
1237The report of pharmacological action is very limited.This research evaluation derive from the Panax notoginseng standard extract P of Radix Notoginseng
1237The inside and outside anti-tumor activity and whether induce the HL-60 apoptosis, tentatively investigated its antineoplastic action mechanism, and its acute toxicity carried out desk study.
Test example 1:
Panax notoginseng standard extract P
1237External influence to growth of human tumor cells propagation:
Along with the increase of concentration, Panax notoginseng standard extract P
1237Inhibitory action to K562, HL-60, COC1, BGC-823 and MCF-7 growth and proliferation of cell strengthens, and presents dose-effect relationship, its IC
50Value is respectively 22.65,28.03 ± 0.37,18.27 ± 12.07,36.20 ± 2.85,27.12 ± 7.19 μ g/ml.The results are shown in Table 1.
Table 1. Panax notoginseng standard extract P
1237Suppression ratio (%) and half-inhibition concentration IC to growth of tumour cell
50(μ g/ml)
Test example 2:
Panax notoginseng standard extract P
1237Influence to the mice transplanted tumor growth:
(1) first batch the results are shown in Table 2
Show by table 2 result: irritate the stomach matched group with feminine gender and compare, the average tumor weight average of each dosage group behind gastric infusion (0.5,1.5,4.5mg/kg) with alleviating in various degree arranged, tumour inhibiting rate is respectively 18.64% (P＞0.05), 17.32% (P＞0.05)
Table 2. Panax notoginseng standard extract P
1237Inhibitory action to the S180 growth
Annotate: compare with po administration negative control group:
*P＜0.01
Compare with ip administration negative control group:
△P＜0.05,
△ △P＜0.01 and 47.84% (P＜0.01).Compare with negative lumbar injection group, the average tumor weight average of lumbar injection low dosage, middle dosage and high dose (0.2mg/kg, 0.6 and 1.8mg/kg) group obviously alleviates, tumour inhibiting rate is respectively 28.05% (P＜0.05), 32.43% (P＜0.05) and 37.46% (P＜0.05), statistical procedures difference has significance.
Panax notoginseng standard extract P
1237Its corresponding negative group comparing difference of the spleen of each test group (thymus) index does not have significance.The body weight of each test group animal of test back all has increase in various degree.
Cisplatin compares with negative lumbar injection group as positive control, and tumour inhibiting rate is 77.59% (P＜0.01), and difference has significance.Body weight of test back animal and preceding apparent in view the alleviating of test, spleen (thymus) index obviously reduces.
(2) second batches the results are shown in Table 3
Table 3. Panax notoginseng standard extract P
1237Inhibitory action (po) to mouse bearing liver cancer H22 growth
Annotate: compare with administration negative control group before the tumor inoculation:
*P＜0.05,
*P＜0.01;
Compare with administration negative control group behind the tumor inoculation:
△ △P＜0.01
According to the result of first test, this test is adjusted, promptly taked administration and two kinds of administering modes of inoculation back administration before the inoculation, set 1,4, three dosage groups of 7mg/kg.The result shows, Panax notoginseng standard extract P
12371,4, each dosage group of 7mg/kg, to H
22The suppression ratio of administration group is respectively 36.83%, 46.01%, 49.12% before the inoculation, and the suppression ratio of inoculation back administration is respectively 38.46%, 41.10%, 46.47%, and suppression ratio increases with the increase of concentration, is dose dependent.With corresponding negative control group relatively, P value is equal＜0.01, difference has significance.
Its corresponding negative group comparing difference of spleen (thymus) index of each test group of Panax notoginseng standard extract P1237 does not have significance, and the body weight of test back animal all has increase in various degree.
VP-16 compares with negative control group as positive control, and tumour inhibiting rate is 60.38% (P＜0.01), and difference has significance.Spleen (thymus) index of test back animal reduces.
(3) the 3rd batches the results are shown in Table 4
According to result of the test several times, this experiment is made as 0.4,2 with dosage, and three dosage groups of 10mg/kg widen the group distance.Again because inoculation forward and backward administration dual mode, also no significant difference are adopted in experiment last time.So this only takes to inoculate the back administration, establishes two kinds of route of administration of po and ip.The result shows that the suppression ratio of po administration group is respectively 16.51% (P＞0.05), 18.59% (P＞0.05), 45.19% (P＜0.01); And
Table 4. Panax notoginseng standard extract P
1237Inhibitory action to mice portability hepatocarcinoma H22 growth
Annotate: compare with po administration negative control group:
*P＜0.01;
Compare with ip administration negative control group:
△ △P＜0.01ip administration group suppression ratio is 18.69% (P＞0.05) respectively, 34.02% (P＜0.01), and 53.71% (P＜0.01) obviously is better than po administration group, and suppression ratio increases with the increase of concentration, is dose dependent.
Panax notoginseng standard extract P
1237Its corresponding negative group comparing difference of the spleen of each test group (thymus) index does not have significance.
Cisplatin compares with negative ip administration group as positive control, and tumour inhibiting rate is 50.49% (P＜0.01), and difference has significance.Relatively preceding with test, spleen (thymus) index of test back animal obviously reduces.
(4) the 4th batches the results are shown in Table 5
Table 5. Panax notoginseng standard extract P
1237Inhibitory action to mouse bearing liver cancer H22 growth
Annotate: compare with po administration negative control group:
*P＜0.05,
*P＜0.01
Compare with ip administration negative control group:
△ △P＜0.01
According to the preceding result of test several times, this experiment has increased a maximum dose level group, can reach maximum tumour inhibiting rate with the Panax notoginseng standard extract P1237 how much dose is tested.The result shows po administration group, and (0.4,2,10, tumour inhibiting rate 20mg/kg) is respectively 17.69% (P＞0.05), 20.23% (P＜0.05), 45.09% (P＜0.01), 45.31% (P＜0.01); Ip administration group (0.4,2,10,20mg/kg) tumour inhibiting rate respectively 22.02%, 38.62%, 53.94%, 55.23%, obviously is better than po administration group, and suppression ratio increases with the increase of concentration, is dose dependent, and P value equal＜0.01.20mg/kg compares with the tumour inhibiting rate of 10mg/kg group, increases not obvious.
Panax notoginseng standard extract P
1237Its corresponding negative group comparing difference of the spleen of each test group (thymus) index does not have significance.
This time experiment positive control DDP group is made as 1.5mg/kg, and very obvious to the inhibitory action of tumor, suppression ratio reaches 86.59% (P＜0.01), but its toxic and side effects is also very obvious.Show as body weight and obviously descend, spleen index, thymus index also obviously reduce.
Test example 3:
Panax notoginseng standard extract P
1237To the apoptotic inducing action of HL-60:
(1) morphocytology changes
HL-60 cell through 100,200 μ g/ml Panax notoginseng standard extract P1237 effects, under the inverted microscope (200 times, 20 * 10), the visible part cell presents the morphological change of apoptosis, and it is irregular to show as cellular morphology, and the film shrinkage appears in part, karyopyknosis, the caryoplasm ratio is dwindled, and parts of fine karyon nuclear membrane disappears, and the nucleus fracture is fritter or fragment shape.The cellular control unit size is than homogeneous, and no had significant proliferation suppresses and morphological change.And administration group cell quantity obviously is less than negative control group.
(2) Panax notoginseng standard extract P
1237Induce HL-60 cell DAN fracture
The HL-60 cell of Panax notoginseng standard extract P1237 100 μ g/ml effect 72h has brown yellow granule to occur in the nucleus.
(3) Panax notoginseng standard extract P
1237To the influence of HL-60 cell cycle distribution and apoptotic detection by quantitative (see Table 7 and Figure 11-14).
Table 7 Panax notoginseng standard extract P
1237Influence and apoptosis rate to the HL-60 cell cycle distribution
| Cell cycle distribution and apoptosis rate (%) | Blank | Panax notoginseng standard extract P1237 (100 μ g/m1) | Panax notoginseng standard extract P1237 (200 μ g/m1) | Positive control (VP-16) |
| G 0/G 1 S G 2/M APO | 55.3 31.7 13.0 0 | 92.5 4.5 3.0 8.2 | 76.4 17.5 6.1 17.6 | 72.5 24.5 3.0 18.8 |
Compare the G0/G of each dosage group of Panax notoginseng standard extract P1237 and VP-16 positive control with the blank group
1The phase cytosis, S phase and G
2/ M phase cell reduces, and the cell generation apoptosis of some is arranged, and increases with the increase of Panax notoginseng standard extract P1237 concentration.The cell S phase 31.7% of blank, G
2/ M phase 13.0%, and G
0/ G
1Phase accounts for 55.3%, illustrates that the HL-60 cell is in the molecular marker for increased proliferation state.The HL-60 cell is through Panax notoginseng standard extract P1237 100ug/ml effect 24h, cell G
0/ G
1Phase accounts for 92.5%, S phase 4.5%, G
2/ M the phase 3.0%; Panax notoginseng standard extract P1237 200 μ g/ml effect 24h, cell G
0/ G
1Phase accounts for 76.4%, S phase 17.5%, G
2/ M the phase 6.1%.
(4) Panax notoginseng standard extract P
1237Influence (seeing Table 8) to HL-60 gene participating in apoptosis Bcl-2 and Bax expression.
Table 8 Panax notoginseng standard extract P1237 is to the influence of HL-60 gene participating in apoptosis Bcl-2 and Bax expression
| Bcl-2 | Bax | |
| Negative Panax notoginseng standard extract P1237 (100 μ g/ml) Panax notoginseng standard extract P1237 (200 μ g/ml) | 4.6 3.5 2.8? | 3.6 7.8 9.0? |
With negative control group relatively, Panax notoginseng standard extract P1237 downward modulation Bcl-2 expression of gene, and along with the increase of concentration, the percentage rate of expressing the Bcl-2 cell descends gradually; Simultaneously Panax notoginseng standard extract P1237 raises the Bax expression of gene, and along with the increase of concentration, the percentage rate of expressing the Bax cell raises gradually, and Bax/Bcl-2＞1.
Test example 4:
Panax notoginseng standard extract P
1237The The acute toxicity tests of its mouse oral and intraperitoneal injection.
(1) the mice body weight change sees Table 9 before and after the experiment:
Mice body weight change before and after table 9 experiment
| Dosage (g/kg) | Route of administration | Body weight (g) before the experiment | Experiment back body weight (g) | ||
| Female | Male | Female | Male | ||
| 2.0 6.08 10.0 | ip po po | 21.08 20.14 20.78 | 21.63 21.42 20.49 | 22.51 23.52 23.31 | 23.89 25.07 24.71 |
(2) observation of mice ordinary circumstance after the administration:
Mice administration drinking-water on the same day and movable minimizing, feed behind the drug withdrawal 12h, drinking-water and movable the recovery normally.Through observing 14d, weight of mice is normal, and fur is breathed steadily along sliding glossy, and is movable normal, do not take place dead.
Can reach a conclusion from above-mentioned result of the test:
1, Panax notoginseng standard extract P
1237Can suppress the propagation of vitro human tumor cell line K562, HL-60, BGC-823, COCl, MCF-7, have than the obvious in-vitro anti-tumor activity.
2, Panax notoginseng standard extract P
1237Growth to S180 and H22 all has the obvious suppression effect, and has shown certain dose-effect relationship, and intraperitoneal injection is better than oral administration; Panax notoginseng standard extract P1237 changes administering mode, and promptly administration does not have obvious difference to the inhibitory action of tumor growth before tumor inoculation and after the inoculation; At the H22 model, the Panax notoginseng standard extract P of oral administration 20mg/kg body weight dosage
1237Compare with 10mg/kg body weight dosage, its active nothing obviously strengthens, and prompting is at the H22 model, and 10mg/kg body weight dosage may be its maximum effective dose; Prompting Panax notoginseng standard extract P
1237Has certain anti-tumor in vivo activity.
3, Panax notoginseng standard extract P
1237Can block the HL-60 cell in G
0/ G
1Phase, and can induce the HL-60 apoptosis, the retardance of cell cycle and cell death inducing may be one of mechanism of its antitumor action, and the generation of apoptosis is relevant with the expression of downward modulation gene participating in apoptosis Bcl-2 and rise Bax.
4, Panax notoginseng standard extract P
1237Do not show overt toxicity, point out its safety higher.
Further specify content of the present invention with embodiments of the invention below, but do not limit the present invention with this.
Embodiment 1:
Panax notoginseng standard extract P
1237Preparation:
Get Radix Notoginseng rhizome 4.8kg, add the ethanol (V/W) of 10 times of amounts 70%, reflux, extract, 3 times, each 2 hours, merge ethanol extract, reclaim solvent, the dry ethanol extraction 1.9kg that gets; Ethanol extraction is with after the low amounts of water dissolving, by D101 macroporous adsorbent resin (15kg, the column chromatography of Φ 20cm * 80cm), discard with the 20kg water elution earlier, reuse 80% ethanol 25kg eluting merges ethanol elution, reclaim solvent, drying obtains Radix Notoginseng total arasaponins 750g; The gained Radix Notoginseng total arasaponins is adsorbed on the silica gel (200～300 order) of 1.5kg with 95% ethanol 3L heating for dissolving, and room temperature volatilizes, and pulverizes, and it is standby to cross 60 mesh sieves; Get 4.5kg silica gel (200～300 order) dress post (Φ 12cm * 120cm), carry out column chromatography for separation; (9: 1: 0.1V/V) mixed solvent eluting, 4L were one and flow part, collect respectively stream part respectively, and the 4th～5 flows a part merging, reclaims solvent, and drying obtains standard extract P with chloroform-methanol-water
1237Pale yellow powder 15g.
Embodiment 2:
With the Panax notoginseng standard extract P that obtains that embodiment 1 separates
1237With the excipient weight ratio be that 9: 1 ratio adds excipient, make powder.
Embodiment 3:
Method by embodiment 1 makes Panax notoginseng standard extract P earlier
1237, be 1 in itself and excipient weight ratio: 5-1: 10 ratio adds excipient, pelletizing press sheet.
Embodiment 4:
Make Panax notoginseng standard extract P earlier
1237, the oral liquid method for making is made oral liquid routinely.
Embodiment 5:
Method by embodiment 1 makes Panax notoginseng standard extract P earlier
1237, be that 5: 1 ratio adds excipient in itself and excipient weight ratio, make capsule or granule or electuary.
Embodiment 6 (take off and state composition, make tablet) by this area conventional method:
Panax notoginseng standard extract P
123750mg
Lactose 70mg
Magnesium stearate 3mg
Polyvinylpyrrolidone 7mg
Add up to 130mg
If desired, tablet can carry out the film coating with hydroxypropyl emthylcellulose, Talcum and coloring agent.
Embodiment 7:
Prepare capsule according to methods known in the art, contain following compositions in each capsule:
Panax notoginseng standard extract P
123750mg
Lactose 70mg
Corn starch 25mg
Magnesium stearate 1mg
Polyvinylpyrrolidone 4mg
Add up to 150mg
Embodiment 8:
The preparation of injection: the method by embodiment 1 or 2 or 3 makes Panax notoginseng standard extract P of the present invention earlier
1237, prepare injection by methods known in the art, add the injection water, fine straining, injection is made in the embedding sterilization.
Claims (7)
1. Panax notoginseng standard extract P
1237, obtain by following method:
Get Radix Notoginseng rhizome 4.8kg, add the ethanol of 10 times of amounts 70% of Radix Notoginseng rhizome, reflux, extract, 3 times, each 2 hours, merge ethanol extract, reclaim solvent, the dry ethanol extraction 1.9kg that gets; After ethanol extraction dissolved with low amounts of water, by 15kg, the D101 macroporous adsorbent resin column chromatography of Φ 20cm * 80cm discarded with the 20kg water elution earlier, and reuse 80% ethanol 25kg eluting merges ethanol elution, reclaims solvent, and drying obtains Radix Notoginseng total arasaponins 750g; The gained Radix Notoginseng total arasaponins is adsorbed on 200～300 order silica gel of 1.5kg with 95% ethanol 3L heating for dissolving, and room temperature volatilizes, and pulverizes, and it is standby to cross 60 mesh sieves; Get 4.5kg200～300 order silica gel dress Φ 12cm * 120cm post, carry out column chromatography for separation; With the chloroform-methanol-water mixed solvent eluting of 9: 1: 0.1 volume ratios, 4L is one and flows part, collects respectively stream part respectively, and the 4th～5 flows a part merging, reclaims solvent, and drying obtains standard extract P
1237Pale yellow powder 15g.
2. Panax notoginseng standard extract P according to claim 1
1237, ginsenoside Rh wherein
4, the ginsenoside Rh
1Be not less than 50% with three kinds of component contents of arasaponin T5.
3. treat the Chinese medicine composition of cancer, by the described Panax notoginseng standard extract P of claim 1
1237And/or pharmaceutically acceptable carrier is formed.
4. the medicine of treatment cancer is a raw material with the Radix Notoginseng, oral liquid or the injection made by following method:
Get Radix Notoginseng rhizome 4.8kg, add the ethanol of 10 times of amounts 70% of Radix Notoginseng rhizome, reflux, extract, 3 times, each 2 hours, merge ethanol extract, reclaim solvent, the dry ethanol extraction 1.9kg that gets; After ethanol extraction dissolves with low amounts of water, by 15kg, the D101 macroporous adsorbent resin column chromatography of Φ 20cm * 80cm, discard with the 20kg water elution earlier, reuse 80% ethanol 25kg eluting merges ethanol elution, reclaim solvent, drying obtains Radix Notoginseng total arasaponins 750g; The gained Radix Notoginseng total arasaponins is adsorbed on 200～300 order silica gel of 1.5kg with 95% ethanol 3L heating for dissolving, and room temperature volatilizes, and pulverizes, and it is standby to cross 60 mesh sieves; Get 4.5kg200～300 order silica gel dress Φ 12cm * 120cm post, carry out column chromatography for separation; With the chloroform-methanol-water mixed solvent eluting of 9: 1: 0.1 volume ratios, 4L is one and flows part, collects respectively stream part respectively, and the 4th～5 flows a part merging, reclaims solvent, and drying obtains standard extract P
1237Pale yellow powder 15g, add then pharmaceutically acceptable carrier routinely formulation method make oral liquid or injection.
5. the described Panax notoginseng standard extract P of claim 1
1237Preparation method, get Radix Notoginseng rhizome 4.8kg, add the ethanol of 10 times of amounts 70% of Radix Notoginseng rhizome, reflux, extract, 3 times, each 2 hours, merge ethanol extract, reclaim solvent, dry ethanol extraction 1.9kg; After ethanol extraction dissolved with low amounts of water, by 15kg, the D101 macroporous adsorbent resin column chromatography of Φ 20cm * 80cm discarded with the 20kg water elution earlier, and reuse 80% ethanol 25kg eluting merges ethanol elution, reclaims solvent, and drying obtains Radix Notoginseng total arasaponins 750g; The gained Radix Notoginseng total arasaponins is adsorbed on 200～300 order silica gel of 1.5kg with 95% ethanol 3L heating for dissolving, and room temperature volatilizes, and pulverizes, and it is standby to cross 60 mesh sieves; Get 4.5kg200～300 order silica gel dress Φ 12cm * 120cm post, carry out column chromatography for separation; With the chloroform-methanol-water mixed solvent eluting of 9: 1: 0.1 volume ratios, 4L is one and flows part, collects respectively stream part respectively, and the 4th～5 flows a part merging, reclaims solvent, and drying obtains standard extract P
1237Pale yellow powder 15g.
6. the described Panax notoginseng standard extract P of claim 1
1237Application in the medicine of preparation treatment Cancerous disease.
7. the application of the described Chinese medicine composition of claim 3 in the medicine of preparation treatment Cancerous disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100581451A CN101244105B (en) | 2008-03-04 | 2008-03-04 | Pseudo-ginseng standard extract P1237, its pharmaceutical combination, its preparing method and its uses |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100581451A CN101244105B (en) | 2008-03-04 | 2008-03-04 | Pseudo-ginseng standard extract P1237, its pharmaceutical combination, its preparing method and its uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101244105A CN101244105A (en) | 2008-08-20 |
| CN101244105B true CN101244105B (en) | 2010-12-15 |
Family
ID=39944924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100581451A Active CN101244105B (en) | 2008-03-04 | 2008-03-04 | Pseudo-ginseng standard extract P1237, its pharmaceutical combination, its preparing method and its uses |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101244105B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526147B (en) * | 2012-03-21 | 2014-04-23 | 北京中海康医药科技发展有限公司 | Method for purifying panax notoginseng total saponins and preparation of panax notoginseng total saponins |
| CN103450308B (en) * | 2013-09-17 | 2015-07-29 | 天津中医药大学 | Compound, its extracting method, comprise its medical composition and its use |
| CN104107203A (en) * | 2014-07-23 | 2014-10-22 | 云南七丹药业股份有限公司 | Process for preparing traditional Chinese medicine extract for reducing blood fat in assisted mode |
| CN104817609B (en) * | 2015-04-01 | 2016-08-24 | 江苏省中医药研究院 | Arasaponin compound with resisting liver cancer activity and preparation method and application |
| CN115216511B (en) * | 2022-09-19 | 2022-12-13 | 长春中医药大学 | Method for preparing rare saponin by fermenting and converting notoginsenoside R1 with lactobacillus plantarum |
-
2008
- 2008-03-04 CN CN2008100581451A patent/CN101244105B/en active Active
Non-Patent Citations (8)
| Title |
|---|
| 吴慧.三七皂苷Pn4的抗肿瘤活性及诱导HL-60细胞凋亡的研究.中国优秀博硕士学位论文全文数据库（硕士） 医药卫生科技辑 （3）.2006,(（3）),E057-64. |
| 吴慧.三七皂苷Pn4的抗肿瘤活性及诱导HL-60细胞凋亡的研究.中国优秀博硕士学位论文全文数据库(硕士) 医药卫生科技辑 (3).2006,((3)),E057-64. * |
| 周家明等.三七根茎的化学成分研究I.中国中药杂志32 （4）.2007,32(（4）),349-350. |
| 周家明等.三七根茎的化学成分研究I.中国中药杂志32 (4).2007,32((4)),349-350. * |
| 宋建平等.三七根茎的化学成分研究（II）.云南大学学报（自然科学版）29 （3）.2007,29(（3）),287-290，296. |
| 宋建平等.三七根茎的化学成分研究(II).云南大学学报(自然科学版)29 (3).2007,29((3)),287-290,296. * |
| 曾江等.三七根茎的化学成分研究.中药材30 （11）.2007,30(（11）),1388-1391. |
| 曾江等.三七根茎的化学成分研究.中药材30 (11).2007,30((11)),1388-1391. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101244105A (en) | 2008-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yao et al. | Traditional Chinese medicine (TCM) as a source of new anticancer drugs | |
| CN112972547B (en) | Traditional Chinese medicine composition for treating qi and blood deficiency syndrome and preparation method and application thereof | |
| CN101822832B (en) | Composition with anti-tumor effect and application thereof in preparing medicament for treating tumor | |
| CN103768534A (en) | Traditional Chinese medicinal composition with anti-tumor activity | |
| CN101244105B (en) | Pseudo-ginseng standard extract P1237, its pharmaceutical combination, its preparing method and its uses | |
| CN101502579B (en) | Chinese medicinal composition for treating digestive tumor and preparation method thereof | |
| CN102114099B (en) | Traditional Chinese medicine preparation for inhibiting liver cancer and preparation method thereof | |
| CN101537036A (en) | Soap pod saponin extract as well as preparation method and application thereof | |
| CN1895337B (en) | Pharmaceutical use of Tangshen and Milkvetch root composition for improving life quality of late tumor patient | |
| CN105399794B (en) | Fructus momordicae triterpene saponin and salt thereof, preparation method and applications of fructus momordicae triterpene saponin and salt thereof, and pharmaceutical composition containing fructus momordicae triterpene saponin and salt thereof | |
| CN105031468B (en) | Fructus Alpinae Oxyphyllae extract with treatment chronic kidney disease effect and its application | |
| CN101564466A (en) | Traditional Chinese medicine effective part composition containing antineoplastic active ingredients as well as preparation method and application thereof | |
| CN103550718B (en) | A kind of Chinese medicine composition for the treatment of pulmonary carcinoma | |
| CN1836665B (en) | Pharmaceutical uses of hesperidin or its composition | |
| CN102858359B (en) | Medicinal composition comprising alcohol-soluble and water-insoluble licorice extract, pharmaceutical preparation, pharmaceutical application, therapeutic method, and preparative method thereof | |
| CN106924331B (en) | Application of Aidi preparation in preparation of medicine for treating neuroblastoma | |
| CN104189782A (en) | Anti-tumor medicament composition | |
| CN101011543B (en) | Antineoplastic medicine composition | |
| CN101019897A (en) | Antitumor medicine composition and its prepn | |
| CN103417906B (en) | Cantharides Chinese medicine composition and the purposes of preparation in preparation medicament for treatment of depression thereof | |
| CN106619613A (en) | Application of bilobalide serving as brain-targeting synergist to preparation of drug for preventing brain tumor | |
| CN101249129B (en) | Chinese medicine extract combination and medicine use thereof | |
| CN102078409B (en) | Traditional Chinese medicine preparation for treating liver cancer | |
| CN106924330B (en) | Application of Aidi preparation in preparation of medicine for resisting malignant pleural mesothelioma | |
| CN106924329B (en) | Application of Aidi preparation in preparation of medicine for treating malignant trophoblastic tumor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: YUNNAN WENSHAN QIDAN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: NOTOGINSENG SCIENCE + TECHNOLOGY INST., WENSHAN ZHUANG + MIAO AUTONOMOUS PREFECT Effective date: 20110819 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20110819 Address after: 663000, No. 72, Jianhe East Road, Kaihua Town, Wenshan County, Yunnan Patentee after: Yunnan Wenshan Qidan Pharmaceutical Co., Ltd. Address before: 663000, No. 99 Sha Bei Road, Kaihua Town, Wenshan County, Yunnan Patentee before: Notoginseng Science & Technology Inst., Wenshan Zhuang & Miao Autonomous Prefect |
|
| C56 | Change in the name or address of the patentee |
Owner name: YUNNAN SEVEN PILL PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: YUNNAN WENSHAN QIDAN PHARMACEUTICAL CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: 663000 37 pharmaceutical industry park, Yunnan, Wenshan Patentee after: Yunnan Qidan Pharmaceutical Co., Ltd. Address before: 663000, No. 72, Jianhe East Road, Kaihua Town, Wenshan County, Yunnan Patentee before: Yunnan Wenshan Qidan Pharmaceutical Co., Ltd. |